Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 12/20 | 0.86 |
| ▸ | KDR | P35968 | 8/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.86 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.86 |
| ▸ | KIT | P10721 | 4/20 | 0.86 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.86 |
| ▸ | RET | P07949 | 3/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.86 |
| ▸ | FLT1 | P17948 | 3/20 | 0.86 |
| ▸ | FLT4 | P35916 | 3/20 | 0.86 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.86 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.86 |
| ▸ | ABL1 | P00519 | 3/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.86 |
| ▸ | STK10 | O94804 | 2/20 | 0.86 |
| ▸ | BCR | P11274 | 2/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.86 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.86 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.86 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083661 | 1.00 | FGFR4 (0.86) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1248140 | 0.94 | FGFR4 (0.87) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1894913 | 0.93 | FGFR4 (0.86) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL30083675 | 0.93 | FGFR4 (0.86) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL864638 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL29349806 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL29372021 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1892035 | 0.92 | FGFR4 (0.73) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL1389214 | 0.92 | FGFR4 (0.98) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1248296 | 0.92 | FGFR4 (0.83) | FGFR4KDRFGFR1PDGFRAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375789-A | Antitumor compound, preparation method thereof, pharmaceutical composition and application | 北京大学第一医院 | 2023-07-04 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-107305202-B | HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard | 北京睿创康泰医药研究院有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-116375789-A | Antitumor compound, preparation method thereof, pharmaceutical composition and application | 北京大学第一医院 | 2023-07-04 | — | — | CN | disclosed |
| CN-115872906-A | Levatinib impurity and preparation method thereof | 山东铂源药业股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-110437223-B | Thiazolone derivative of lenetinic acid and application thereof | 江苏千之康生物医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021023016-A1 | THIAZOLIDONE DERIVATIVE OF LOVATINIB ACID AND APPLICATION THEREOF | 江苏千之康生物医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| CN-107305202-B | HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard | 北京睿创康泰医药研究院有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10550086-B1 | Lenvatinib derivative, and composition for pharmaceutical research and tumor therapeutic agent using the same | INSTITUTE OF APPLIED BIOCHEMISTRY (JP) | 2020-02-04 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | FGFR4 682/4885KDR 22/4885FGFR1 165/4885 |
| US-10550086-B1 | Lenvatinib derivative, and composition for pharmaceutical research and tumor therapeutic agent using the same | FLT1, FLT4, KDR | FGFR4 62/4885KDR 3/4885FGFR1 58/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | FGFR4 1688/4885KDR 60/4885FGFR1 445/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | FGFR4 1688/4885KDR 60/4885FGFR1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.